• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?

    Simply Wall St·04/06/2026 01:19:47
    Listen to the news
    • Precigen, Inc. has reported full-year 2025 results, with revenue rising to US$9.68 million from US$3.93 million, while net loss widened to US$250.64 million and basic loss per share from continuing operations increased to US$1.37 from US$0.47, ahead of a recent virtual fireside chat with H.C. Wainwright.
    • The combination of sharply higher revenue and a very large year-on-year increase in net loss gives investors new data on how Precigen’s growth efforts are affecting its financial profile.
    • We will now examine how the very large widening in Precigen’s annual net loss may influence the company’s longer-term investment narrative.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Precigen Investment Narrative Recap

    To own Precigen, you need to believe PAPZIMEOS can grow into a meaningful, durable therapy for recurrent respiratory papillomatosis while the company manages heavy upfront investment and ongoing losses. The 2025 results, with modest revenue and a sharply wider net loss, keep the near term focus squarely on commercialization progress and cash needs; the latest numbers do not yet change the central catalyst of PAPZIMEOS uptake, but they do add weight to dilution and financing risk in the short term.

    The most relevant recent development is the full year 2025 earnings release, which puts hard figures around the early PAPZIMEOS launch. Revenue more than doubled year on year to US$9.68 million, but the net loss grew to US$250.64 million, highlighting how dependent the long term story is on converting the estimated adult RRP opportunity efficiently into sales. How quickly that gap narrows will be central to how investors view the sustainability of the business model.

    Yet against this progress, investors should be aware that any delay in translating PAPZIMEOS demand into revenue could...

    Read the full narrative on Precigen (it's free!)

    Precigen's narrative projects $299.5 million revenue and $118.4 million earnings by 2028. This requires 262.1% yearly revenue growth and a $544.3 million earnings increase from $-425.9 million today.

    Uncover how Precigen's forecasts yield a $8.50 fair value, a 116% upside to its current price.

    Exploring Other Perspectives

    PGEN 1-Year Stock Price Chart
    PGEN 1-Year Stock Price Chart

    Eleven fair value estimates from the Simply Wall St Community span a wide range, from US$0.50 to US$41.10 per share, reflecting very different views on Precigen’s potential. Set against this dispersion, the recent surge in losses relative to early PAPZIMEOS revenue underlines why opinions on future execution and funding needs can vary so widely, and why it is worth comparing several independent viewpoints before forming a view on the stock.

    Explore 11 other fair value estimates on Precigen - why the stock might be worth over 10x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In Precigen?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.